Cohance Lifesciences

    COHANCE
    Pharma
    ₹456.40
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹17,463 Cr

    P/E
    383.53
    Day range
    ₹445.25 – ₹457.95
    52-week range
    ₹266.70 – ₹601.85
    Volume
    2.50 L
    Open
    ₹452.00
    Prev close
    ₹451.60

    Latest results · Q2 FY27(consolidated)Revenue ₹477 Cr-56.9%Profit ₹2 Cr-98.0%Margin 0.5%YoY vs the same quarter last year

    1 red flag to read up on

    • high

      High promoter pledge

      94.56% of promoter shares pledged · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 35 / 100

    Factor percentiles

    Value32
    Quality25
    Momentum54
    Low volatility30

    Derived metrics

    Earn. yield
    0.3%
    Graham no.
    ₹53.94
    vs Graham
    -88.2%
    ROE ÷ P/B
    0.9%
    12-1 mom.
    -34.2%
    Return / vol
    -0.74
    Magic Formula
    #611
    Piotroski
    2/6
    FCF yield
    0.9%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Cohance LifesciencesCOHANCE₹17,463 Cr383.534.504.0%6.0%7.4%0.11-14.2%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 2h ago

    Headlines about Cohance Lifesciences from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    358.0
    Price / Book
    4.47
    ROE (FY26)
    4.0%
    ROCE (latest year)
    6%
    Dividend yield
    0.00%

    Moving averages (NSE)

    20-day
    ₹456.7
    Price below
    50-day
    ₹452.03
    Price above
    200-day
    ₹411.27
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +19.2%
    Profit 3Y CAGR
    -28.5%
    Revenue YoY (Sep 2026)
    -14.2%
    Profit YoY (Sep 2026)
    -96.6%
    Operating margin
    7.4%
    Net margin
    0.5%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    -250 Cr0 Cr250 Cr500 Cr750 Cr1K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%20%40%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • DII
    • Public
    • FII
    • Government

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-500 Cr0 Cr500 Cr1K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY20FY21FY22FY23FY24FY25FY260%20%40%60%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr1K Cr2K Cr3K Cr4K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY22FY23₹0₹2₹4₹6

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales219.82252.93488.08603.77676.23840.42549.31555.57544.55619.12422.26476.65
    YoY Sales growth-37.86-31.52—————-7.98-19.47-26.33-23.13-14.21
    Expenses153.74179.58362.98398.40438.86611.20437.30434.62449.20520.44421.10441.27
    Operating Profit66.0873.35125.10205.37237.37229.22112.01120.9595.3598.681.1635.38
    OPM %30.1%29%25.6%34.0%35.1%27.3%20.4%21.8%17.5%15.9%0.3%7.4%
    Other Income14.3417.0519.4116.1921.56-3.736.0715.601.30-18.3512.2512.41
    Interest2.162.3010.209.6110.8010.4510.188.769.119.196.748.37
    Depreciation12.7917.2531.2837.7943.5654.1745.1444.0246.9451.2349.5450.17
    Profit before tax65.4770.85103.03174.16204.57160.8762.7683.7740.6019.91-42.87-10.75
    Tax %28.6%24.7%26.9%20.6%25.0%27.2%26.1%20.8%28.5%58.3%5.4%-121.1%
    Net Profit46.7553.3775.37138.24153.48117.1546.4066.3929.028.31-45.192.27
    EPS in Rs₹1.84₹2.10₹2.96₹5.44₹6.01₹4.73₹1.28₹1.94₹0.96₹0.51₹-0.63₹0.40

    From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days110

    +73 days since Mar 2021

    Inventory Days310

    +67 days since Mar 2021

    Days Payable157

    +57 days since Mar 2021

    Cash Conversion Cycle263

    +83 days since Mar 2021

    Working Capital Days133

    +77 days since Mar 2021

    Strengths, risks & growth

    Cohance Lifesciences is a Hyderabad-based CDMO operating across pharmaceutical development, manufacturing, APIs, formulations and specialty chemicals. The company states that it features among the Top 20 CDMOs globally; its Pharma CDMO business works with 19 of the top 20 global innovators, while the API portfolio ranks among the top three suppliers in 8 of its top 10 molecules. [1] [2]

    Strengths

    None flagged by the checklist.

    Risks

    • Though the company is reporting repeated profits, it is not paying out dividend
    • Company has low interest coverage ratio.
    • Company has a low return on equity of 10.6% over last 3 years.
    • Promoters have pledged 94.6% of their holding.
    • Debtor days have increased from 88.0 to 110 days.

    Compounded Sales Growth

    10 Years
    —
    5 Years
    +18%
    3 Years
    +19%
    TTM
    -21%

    Compounded Profit Growth

    10 Years
    —
    5 Years
    -12%
    3 Years
    -23%
    TTM
    -88%

    Stock Price CAGR

    10 Years
    —
    5 Years
    -2%
    3 Years
    -8%
    1 Year
    -22%

    Return on Equity

    10 Years
    —
    5 Years
    +15%
    3 Years
    +11%
    Last Year
    +5%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter57.49%57.49%57.49%57.48%-0.01 pp
    FII6.01%5.59%6.50%7.71%+1.21 pp
    DII21.57%21.79%20.09%18.86%-1.23 pp
    Government0.01%0.01%0.01%0.00%-0.01 pp
    Public14.91%15.11%15.92%15.95%+0.03 pp

    Filed with NSE for Sept 2026: promoters 57.48%, public 42.52%

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    47.7%
    Downside volatility
    41.4%
    Worst 5% of days
    4.2%
    Average of that tail
    6.3%
    Max drawdown (1Y)
    71.9%
    Below its peak
    54.2%

    Against the market

    Beta vs Nifty 50
    0.75
    Correlation
    0.21
    Relative strength (3M)
    -1.3%
    ATR (14)
    3.8%

    Return

    Return 1M
    -1.6%
    Return 3M
    +2.6%
    Return 6M
    +6.6%
    Return 1Y
    -35.3%
    vs 200-day average
    +11.0%

    Momentum

    RSI (14)
    50.8
    MACD histogram
    0.03
    Stochastic %K
    46.1
    ADX (14)
    10.8
    +DI / −DI
    21.4 / 22.5
    Money flow index
    56.1

    Participation

    Delivery (20d avg)
    41.6%
    vs its 60-day baseline
    -3.7 pts
    Volume vs 20-day
    -1.0σ
    Close vs day's VWAP
    +0.7%
    52-week position
    25 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    2 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — failed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — failed
    • Asset turnover improving — failed
    Free cash flow
    ₹148 Cr
    FCF yield
    0.9%
    Cash conversion
    1.87
    Accruals ratio
    -0.030
    Net debt
    ₹350 Cr
    Net debt / equity
    0.09
    EV / sales
    8.64
    Capex intensity
    7.8%
    Revenue CAGR
    -56.9%
    Profit CAGR
    -98.0%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • other
      Not available — not reported in this filing

      Annual General Meeting

      6 Aug 2024
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      12 Dec 2023
      ex-date
    • dividend
      ₹5.00

      Interim Dividend - Re 1 Per Share/Special Dividend- Rs 5 Per Share

      9 Sept 2022
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      11 Aug 2022
      ex-date
    • dividend
      Not available — not reported in this filing

      Interim Dividend - Re 1 Per Share/Special Dividend - Re 1 Per Share

      13 May 2022
      ex-date
    • dividend
      ₹2.00

      Interim Dividend - Re 1 Per Share/ Special Dividend - Rs 2 Per Share

      15 Feb 2022
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting/Dividend - Re 1 Per Share

      13 Aug 2021
      ex-date
    • dividend
      Not available — not reported in this filing

      Interim Dividend - Re 1 Per Share

      17 Feb 2021
      ex-date
    • bonus
      Not available — not reported in this filing

      Bonus 1:1

      25 Sept 2020
      ex-date

    Company announcements

    Company Update
    General Updates

    General updates

    Company Update
    Grant Of Stock Options To Certain Eligible Employees Of The Company

    Grant of Stock options to certain eligible employees of the Company

    Company Update
    Announcement under Regulation 30 (LODR)-Change in Management

    Appointment of Mr. Abhimanyu Ojha as Chief Financial Officer of the Company

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Compliance Certificate under 74(5) of SEBI (DP) Regulations 2018

    Company Update
    ESG Rating By Crisil ESG Ratings & Analytics Limited

    ESG Rating by Crisil ESG ratings & Analytics Limited

    Insider Trading / SAST
    Closure of Trading Window
    Company Update
    General Upadte

    General update

    Company Update
    General Update

    General update

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Scrutinizer`s report

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Proceedings of Annual General Meeting

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Investor Meet

    Company Update
    Completion Of USFDA Inspection

    Completion of USFDA Inspection

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Press Release

    Others
    Board Meeting Outcome for Outcome Of The Committee Meeting

    Outcome of Committee Meeting

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Investors Meet

    Filed with BSE (scrip 543064); the last 45 days. Documents open at bseindia.com.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 7 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Cohance Lifesciences: common questions

    Answered from the figures on this page.

    Cohance Lifesciences last traded at ₹456.40 (NSE, as of 18 Nov 2026). The last session moved it up 1.06%.

    Cohance Lifesciences is valued at about ₹17,463 crore (NSE, as of 18 Nov 2026).

    Cohance Lifesciences trades at a price-to-earnings ratio of 383.53 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Cohance Lifesciences has traded between ₹266.70 and ₹601.85 over the past 52 weeks, to 18 Nov 2026. It is currently 57% of the way up that range.

    Cohance Lifesciences (COHANCE) is classified under Pharma on this site's screener.